2023-08-14 09:44:20 ET
- POINT Biopharma Global press release ( NASDAQ: PNT ): Q2 GAAP EPS of -$0.24.
- Revenue of $4.87M.
For further details see:
POINT Biopharma Global GAAP EPS of -$0.24, revenue of $4.87M2023-08-14 09:44:20 ET
For further details see:
POINT Biopharma Global GAAP EPS of -$0.24, revenue of $4.87MMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
POINT Biopharma Global Inc. Company Name:
PNT Stock Symbol:
Market:
POINT Biopharma Global Inc. Website:
NORTHAMPTON, MA / ACCESSWIRE / June 25, 2024 / Pentair Greg Claffey, Group President, Pentair Pool (right) presents Pentair Pool Step Into Swim sponsorship check to Rowdy Gaines, Vice President Partnerships and Development, PHTA, and Olympic Gold Medalist. As published on the Pentair Blog . ...
LONDON, UK / ACCESSWIRE / April 18, 2024 / Pentair plc (NYSE:PNR), a leader in helping the world sustainably move, improve and enjoy water, life's most essential resource, today released its 2023 Corporate Responsibility Report, reporting on the Company's efforts and progress toward Making Bett...
Lilly Completes Acquisition of POINT Biopharma PR Newswire INDIANAPOLIS , Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceuti...